Translational oncology scientist with 15+ years in drug discovery, spanning target identification and validation, mechanism of action, and in vivo efficacy. Designed and led 40+ preclinical studies in immunocompetent, orthotopic, and carcinogen-induced solid tumor models, generating efficacy, pharmacodynamic, and biomarker data used for target prioritization, candidate selection, and combination rationale. Technical depth in CRISPR/Cas9 target validation, multiparameter flow cytometry, and bulk and single-cell RNA-seq. Author of 24 peer-reviewed papers (10 first author), 1,380+ citations.